Press releasePRNewswire
Kazia Therapeutics
KZIA · NASDAQ
$7.81−$0.26 (−3.22%)TodayMarket closed ·
Prev close $8.07
Latest news
- Press releasePRNewswire
Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer
- Press releasePRNewswire
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
- Press releasePRNewswire
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer
- Press releasePRNewswire
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering
- Press releasePRNewswire
Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering
- Press releasePRNewswire
Kazia Therapeutics Limited Announces Proposed Public Offering
- Press releasePRNewswire
Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer
- Press releaseGlobe Newswire
Kazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer
- Press releaseGlobe Newswire
The Multi-Billion-Dollar Search for Better Glioblastoma Treatments
- Press releasePRNewswire
Kazia Therapeutics Appoints James Levine as Chief Financial Officer
- Press releasePRNewswire
Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
- Press releasePRNewswire
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
- Press releasePRNewswire
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- Press releasePRNewswire
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
- NewsVandana Singh
Kazia Therapeutics Reports Positive Early Responses In Aggressive Breast Cancer Trial
- Press releasePRNewswire
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
- Press releasePRNewswire
Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End
- Press releasePRNewswire
How $594B in Precision Tech is Cracking the Metastatic Cancer Code
- NewsAvi Kapoor
Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
- Press releasePRNewswire
Kazia Therapeutics Regains Full Nasdaq Listing Compliance
- Press releasePRNewswire
Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+
- NewsVandana Singh
What's Going On With Cancer Firm Kazia Therapeutics
- Press releasePRNewswire
Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
Market-Moving News for November 19th
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Press releasePRNewswire
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy
- Press releasePRNewswire
Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner
- Press releasePRNewswire
Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program
- Press releasePRNewswire
Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen
- Press releasePRNewswire
Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- NewsAvi Kapoor
Why SolarEdge Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.